About Leucine-rich alpha-2-glycoprotein
Leucine-rich alpha-2-glycoprotein (LRG1) is a protein
from Homo sapiens identified by UniProt accession
P02750, 347 residues long.
MolForge cross-references it against 0 known binders and
298 disease associations.
Target properties
| Protein name | Leucine-rich alpha-2-glycoprotein |
|---|
| UniProt accession | P02750 |
|---|
| Gene | LRG1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 347 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (298)
Diseases linked to this target (Open Targets).
- plasma leucine rich alpha-2-glycoprotein 1 measurement · score 0.20
- allergic disease · score 0.14
- nonpapillary renal cell carcinoma · score 0.10
- non-small cell lung carcinoma · score 0.09
- colorectal carcinoma · score 0.09
- esophageal squamous cell carcinoma · score 0.09
- neoplasm · score 0.09
- mucocutaneous lymph node syndrome · score 0.09
- Obesity · score 0.09
- Osteoporosis · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P02750-F1 | alphafold | PREDICTED | 89.72 | — |
Amino-acid sequence (347 residues)
MSSWSRQRPK SPGGIQPHVS RTLFLLLLLA ASAWGVTLSP KDCQVFRSDH GSSISCQPPA EIPGYLPADT VHLAVEFFNL THLPANLLQG ASKLQELHLS SNGLESLSPE FLRPVPQLRV LDLTRNALTG LPPGLFQASA TLDTLVLKEN QLEVLEVSWL HGLKALGHLD LSGNRLRKLP PGLLANFTLL RTLDLGENQL ETLPPDLLRG PLQLERLHLE GNKLQVLGKD LLLPQPDLRY LFLNGNKLAR VAAGAFQGLR QLDMLDLSNN SLASVPEGLW ASLGQPNWDM RDGFDISGNP WICDQNLSDL YRWLQAQKDK MFSQNDTRCA GPEAVKGQTL LAVAKSQ
Explore Leucine-rich alpha-2-glycoprotein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets